[1]谢小街,黄凤梅,王满琴,等.氯沙坦钾片联合黄葵胶囊和贝前列素钠片对腹膜透析患者腹透液蛋白丢失的影响[J].医学信息,2019,32(24):136-137.[doi:10.3969/j.issn.1006-1959.2019.24.048]
 XIE Xiao-jie,HUANG Feng-mei,WANG Man-qin,et al.Effect of Losartan Potassium Tablets,Huangkui Capsules,and Beprost Sodium Tablets on Peritoneal Fluid Protein Loss in Patients with Peritoneal Dialysis[J].Medical Information,2019,32(24):136-137.[doi:10.3969/j.issn.1006-1959.2019.24.048]
点击复制

氯沙坦钾片联合黄葵胶囊和贝前列素钠片对腹膜透析患者腹透液蛋白丢失的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年24期
页码:
136-137
栏目:
药物与临床
出版日期:
2019-12-15

文章信息/Info

Title:
Effect of Losartan Potassium Tablets,Huangkui Capsules,and Beprost Sodium Tablets on Peritoneal Fluid Protein Loss in Patients with Peritoneal Dialysis
文章编号:
1006-1959(2019)24-0136-02
作者:
谢小街1黄凤梅2王满琴1杨尚凌1顾佳龙1陈 建1
(联勤保障部队第九〇八医院肾内科1,重症医学科2,江西 鹰潭 335000)
Author(s):
XIE Xiao-jie1HUANG Feng-mei2WANG Man-qin1YANG Shang-ling1GU Jia-long1CHEN Jian1
(Department of Nephrology1,Department of Critical Care Medicine2,the 908th Hospital of the Joint Logistics Support Force,Yingtan 335000,Jiangxi,China)
关键词:
腹膜透析氯沙坦钾片黄葵胶囊贝前列素钠片腹透液蛋白丢失
Keywords:
Peritoneal dialysisLosartan potassium tabletsHuangkui capsulesBeprost sodium tabletsPeritoneal fluid protein loss
分类号:
R459.5
DOI:
10.3969/j.issn.1006-1959.2019.24.048
文献标志码:
A
摘要:
目的 探讨氯沙坦钾片联合黄葵胶囊和贝前列素钠片对腹膜透析患者腹透液蛋白丢失的影响。方法 选取2018年3月~2019年8月我院收治的腹膜透析患者60例作为研究对象,均给予常规透析后加用氯沙坦钾片联合黄葵胶囊和贝前列素钠片,比较治疗前与治疗后3个月血浆白蛋白及腹膜透析液中总蛋白、微量蛋白水平。结果 治疗后3个月,患者血浆白蛋白水平高于治疗前,总蛋白、微量蛋白水平低于治疗前,差异具有统计学意义(P<0.05)。治疗后不良反应发生率为6.67%(4/60)。结论 氯沙坦钾片联合黄葵胶囊和贝前列素钠片治疗腹膜透析患者,可提高患者血浆白蛋白水平,降低腹膜透析液中总蛋白、微量蛋白水平,且不良反应轻微,对腹膜透析治疗效果具有一定促进作用。
Abstract:
Objective To investigate the effect of losartan potassium tablets combined with Huangkui capsules and beprost sodium tablets on protein loss of peritoneal fluid in patients with peritoneal dialysis. Methods 60 patients with peritoneal dialysis admitted in our hospital from March 2018 to August 2019 were selected as the research subjects. All patients were given losartan potassium tablets combined with Huangkui capsules and beprost sodium tablets after routine dialysis. And 3 months after treatment with plasma albumin and peritoneal dialysate total protein, trace protein levels. Results Three months after treatment, the patient’s plasma albumin level was higher than that before treatment, and total protein and trace protein levels were lower than before treatment, the difference was statistically significant (P<0.05). The incidence of adverse reactions after treatment was 6.67% (4/60). Conclusion Losartan potassium tablets combined with Huangkui capsules and beprostone sodium tablets in patients with peritoneal dialysis can increase patients’ plasma albumin levels, reduce total protein and trace protein levels in peritoneal dialysate, and have minor adverse reactions. The effect has a certain promoting effect.

参考文献/References:

[1]林叶,陈文,庄乙君,等.20、40 mg辛伐他汀与氯沙坦钾联合口服对腹膜透析患者氧化应激和炎症因子水平的影响[J].山东医药,2017,57(39):79-81.[2]罗富里,杨林,稂春燕,等.血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂对维持性腹膜透析患者腹膜透出液蛋白含量的影响[J].中华肾脏病杂志,2014,30(8):575-579.[3]程锦绣,陆继芳,李玥欣,等.尿毒清颗粒联合氯沙坦钾对腹膜透析患者微炎症状态及腹膜功能的影响[J].实用临床医药杂志,2017,21(23):46-49.[4]Polatdemir E,Demirkayamiloglu F,Senol O,et al.Design and Optimization of a Novel Spectrophotometric Method using Response Surface Methodology for the Determination of Losartan Potassium in Pharmaceuticals[J].Current Pharmaceutical Analysis,2017,13(6):133-135.[5]罗明乾,石晓峰,黄美莲,等.贝前列素钠在防治维持性血液透析患者动静脉移植物内瘘并发症中的应用[J].国际移植与血液净化杂志,2018,16(4):16-19.

相似文献/References:

[1]林子娟,王美玲,王 芳.基于CiteSpace软件的腹膜透析护理文献计量学研究[J].医学信息,2022,35(15):32.[doi:10.3969/j.issn.1006-1959.2022.15.006]
 LIN Zi-juan,WANG Mei-lin,WANG Fang.Bibliometric Study on Peritoneal Dialysis Nursing Based on CiteSpace Software[J].Medical Information,2022,35(24):32.[doi:10.3969/j.issn.1006-1959.2022.15.006]
[2]徐海红,刘 宇,宋桂云.腹膜透析患者认知功能障碍对日常透析操作影响的研究[J].医学信息,2022,35(15):110.[doi:10.3969/j.issn.1006-1959.2022.15.025]
 XU Hai-hong,LIU Yu,SONG Gui-yun.Study on the Effect of Cognitive Dysfunction in Peritoneal Dialysis Patients on Daily Dialysis Operation[J].Medical Information,2022,35(24):110.[doi:10.3969/j.issn.1006-1959.2022.15.025]
[3]陶秀波.腹膜透析患者自我护理能力现状及影响因素分析[J].医学信息,2020,33(13):177.[doi:10.3969/j.issn.1006-1959.2020.13.057]
 TAO Xiu-bo.Analysis of Current Status and Influencing Factors of Self-care Ability of Peritoneal Dialysis Patients[J].Medical Information,2020,33(24):177.[doi:10.3969/j.issn.1006-1959.2020.13.057]
[4]何媛梅,黄楚乔,邓兆燕,等.腹膜透析相关性腹膜炎的细菌谱及耐药性分析[J].医学信息,2020,33(16):135.[doi:10.3969/j.issn.1006-1959.2020.16.042]
 HE Yuan-mei,HUANG Chu-qiao,DENG Zhao-yan,et al.Analysis of Bacterial Spectrum and Drug Resistance of Peritonitis Associated with Peritoneal Dialysis[J].Medical Information,2020,33(24):135.[doi:10.3969/j.issn.1006-1959.2020.16.042]
[5]徐海红,闫 巍,陈 晶,等.腹膜透析患者认知功能障碍的相关因素分析[J].医学信息,2022,35(23):80.[doi:10.3969/j.issn.1006-1959.2022.23.013]
 XU Hai-hong,YAN Wei,CHEN Jing,et al.Analysis of the Related Factors to the Cognitive Dysfunction of the Patients with Peritoneal Dialysis[J].Medical Information,2022,35(24):80.[doi:10.3969/j.issn.1006-1959.2022.23.013]
[6]骆 楠.腹膜透析患者微炎症和铁负荷的关系[J].医学信息,2021,34(09):131.[doi:10.3969/j.issn.1006-1959.2021.09.035]
 LUO Nan.The Relationship Between Microinflammation and Iron Load in Peritoneal Dialysis Patients[J].Medical Information,2021,34(24):131.[doi:10.3969/j.issn.1006-1959.2021.09.035]
[7]邓雯懿,徐国玉,刘国辉.老年营养风险指数在评估维持性腹膜透析患者营养中的应用[J].医学信息,2021,34(16):47.[doi:10.3969/j.issn.1006-1959.2021.16.013]
 DENG Wen-yi,XU Guo-yu,LIU Guo-hui.Application of Elderly Nutritional Risk Index in Evaluating Nutrition of Maintenance Peritoneal Dialysis Patients[J].Medical Information,2021,34(24):47.[doi:10.3969/j.issn.1006-1959.2021.16.013]
[8]傅 强,李志樑,周柏华,等.射血分数保留的心力衰竭合并终末期肾病不同透析方式的死亡率比较[J].医学信息,2022,35(02):110.[doi:10.3969/j.issn.1006-1959.2022.02.026]
 FU Qiang,LI Zhi-liang,ZHOU Bai-hua,et al.Comparison of Mortality Rates Under Different Dialysis Methods in Patients with Heart Failure with Preserved Ejection Fraction Combined with End-stage Renal Disease[J].Medical Information,2022,35(24):110.[doi:10.3969/j.issn.1006-1959.2022.02.026]

更新日期/Last Update: 2019-12-15